{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T02:11:52Z","timestamp":1648951912120},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00066-021-01755-8","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T17:03:31Z","timestamp":1616432611000},"page":"449-451","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Verschlechterung der Lebensqualit\u00e4t von Patienten mit Morbus Hodgkin in den folgenden 5\u00a0Jahren nach abgeschlossener Therapie: Langzeitdaten aus den Studien HD13, HD14 und HD15"],"prefix":"10.1007","volume":"197","author":[{"given":"Dirk","family":"Vordermark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"9976","key":"1755_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer\u00a0K, Goergen\u00a0H, Hitz\u00a0F, Zijlstra\u00a0JM, Greil\u00a0R, Markova\u00a0J, Sasse\u00a0S, Fuchs\u00a0M, Topp\u00a0MS, Soekler\u00a0M, Mathas\u00a0S, Meissner\u00a0J, Wilhelm\u00a0M, Koch\u00a0P, Lindemann\u00a0HW, Schalk\u00a0E, Semrau\u00a0R, Kriz\u00a0J, Vieler\u00a0T, Bentz\u00a0M, Lange\u00a0E, Mahlberg\u00a0R, Hassler\u00a0A, Vogelhuber\u00a0M, Hahn\u00a0D, Mezger\u00a0J, Krause\u00a0SW, Skoetz\u00a0N, B\u00f6ll\u00a0B, von Tresckow\u00a0B, Diehl\u00a0V, Hallek\u00a0M, Borchmann\u00a0P, Stein\u00a0H, Eich\u00a0H, Engert\u00a0A, German Hodgkin Study Group Swiss Group for Clinical Cancer Research (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385(9976):1418\u20131427","journal-title":"Lancet"},{"issue":"9","key":"1755_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow\u00a0B, Pl\u00fctschow\u00a0A, Fuchs\u00a0M, Klimm\u00a0B, Markova\u00a0J, Lohri\u00a0A, Kral\u00a0Z, Greil\u00a0R, Topp\u00a0MS, Meissner\u00a0J, Zijlstra\u00a0JM, Soekler\u00a0M, Stein\u00a0H, Eich\u00a0HT, Mueller\u00a0RP, Diehl\u00a0V, Borchmann\u00a0P, Engert\u00a0A (2012) Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J\u00a0Clin Oncol 30(9):907\u2013913","journal-title":"J Clin Oncol"},{"issue":"9828","key":"1755_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert\u00a0A, Haverkamp\u00a0H, Kobe\u00a0C, Markova\u00a0J, Renner\u00a0C, Ho\u00a0A, Zijlstra\u00a0J, Kr\u00e1l\u00a0Z, Fuchs\u00a0M, Hallek\u00a0M, Kanz\u00a0L, D\u00f6hner\u00a0H, D\u00f6rken\u00a0B, Engel\u00a0N, Topp\u00a0M, Klutmann\u00a0S, Amthauer\u00a0H, Bockisch\u00a0A, Kluge\u00a0R, Kratochwil\u00a0C, Schober\u00a0O, Greil\u00a0R, Andreesen\u00a0R, Kneba\u00a0M, Pfreundschuh\u00a0M, Stein\u00a0H, Eich\u00a0HT, M\u00fcller\u00a0RP, Dietlein\u00a0M, Borchmann\u00a0P, Diehl\u00a0V, German Hodgkin Study Group Swiss Group for Clinical Cancer Research (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a\u00a0randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791\u20131799","journal-title":"Lancet"},{"issue":"2","key":"1755_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch\u00a0E, Deal\u00a0AM, Dueck\u00a0AC, Scher\u00a0HI, Kris\u00a0MG, Hudis\u00a0C, Schrag\u00a0D (2017) Overall survival results of a\u00a0trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197\u2013198","journal-title":"JAMA"},{"issue":"4","key":"1755_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ijrobp.2009.12.054","volume":"79","author":"W Machann","year":"2011","unstructured":"Machann\u00a0W, Beer\u00a0M, Breunig\u00a0M, St\u00f6rk\u00a0S, Angermann\u00a0C, Seufert\u00a0I, Schwab\u00a0F, K\u00f6lbl\u00a0O, Flentje\u00a0M, Vordermark\u00a0D (2011) Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin\u2019s disease. Int J Radiat Oncol Biol Phys 79(4):1117\u20131123","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"1755_CR6","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","volume":"28","author":"C Mauz-K\u00f6rholz","year":"2010","unstructured":"Mauz-K\u00f6rholz\u00a0C, Hasenclever\u00a0D, D\u00f6rffel\u00a0W, Ruschke\u00a0K, Pelz\u00a0T, Voigt\u00a0A, Stiefel\u00a0M, Winkler\u00a0M, Vilser\u00a0C, Dieckmann\u00a0K, Karl\u00e9n\u00a0J, Bergstr\u00e4sser\u00a0E, Foss\u00e5\u00a0A, Mann\u00a0G, Hummel\u00a0M, Klapper\u00a0W, Stein\u00a0H, Vordermark\u00a0D, Kluge\u00a0R, K\u00f6rholz\u00a0D (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002\u00a0study. J\u00a0Clin Oncol 28(23):3680\u20133686","journal-title":"J Clin Oncol"},{"issue":"1","key":"1755_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12955-016-0515-6","volume":"14","author":"N Linendoll","year":"2016","unstructured":"Linendoll\u00a0N, Saunders\u00a0T, Burns\u00a0R, Nyce\u00a0JD, Wendell\u00a0KB, Evens\u00a0AM, Parsons\u00a0SK (2016) Health-related quality of life in Hodgkin lymphoma: a\u00a0systematic review. Health Qual Life Outcomes 14(1):114","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1755_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00433921","volume":"5","author":"J Norum","year":"1996","unstructured":"Norum\u00a0J, Wist\u00a0EA (1996) Quality of life in survivors of Hodgkin\u2019s disease. Qual Life Res 5(3):367\u2013374","journal-title":"Qual Life Res"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01755-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T15:09:33Z","timestamp":1622646573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01755-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"8 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Vordermark gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}